| 1 |
Gabbia D, De Martin S. Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma. Int J Mol Sci 2023;24. [PMID: 36834851 DOI: 10.3390/ijms24043441] [Reference Citation Analysis]
|
| 2 |
Zhang Q, Huang Y, Xia Y, Liu Y, Gan J. Cuproptosis-related lncRNAs predict the prognosis and immune response in hepatocellular carcinoma. Clin Exp Med. [DOI: 10.1007/s10238-022-00892-3] [Reference Citation Analysis]
|
| 3 |
Yu J, Sun X, Zhao Y, Zheng C, Zhou B. Development and Validation of an Individualized Immune Prognostic Signature in HNSCC.. [DOI: 10.21203/rs.3.rs-2007096/v1] [Reference Citation Analysis]
|
| 4 |
Català-senent JF, Andreu Z, Hidalgo MR, Roig FJ, Yanguas-casás N, Neva-alejo A, López-cerdán A, Soler-sáez I, Iglesia-vayá MDL, Stranger BE, Garcia FG. A Deep Transcriptome Meta-Analysis Reveals Sex Differences in Multiple Sclerosis.. [DOI: 10.21203/rs.3.rs-2011220/v1] [Reference Citation Analysis]
|
| 5 |
Liu Z, Zhang D, Lin X, Sun J, Abuduwaili W, Zhang G, Xu R, Wang F, Yu X, Shi X, Deng B, Dong L, Weng S, Zhu J, Shen X, Liu T. Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma via the tumor immune microenvironment analysis. Front Pharmacol 2022;13:952482. [DOI: 10.3389/fphar.2022.952482] [Reference Citation Analysis]
|
| 6 |
Yang H, Jiang Q. A multi-omics-based investigation of the immunological and prognostic impact of necroptosis-related genes in patients with hepatocellular carcinoma. J Clin Lab Anal 2022;:e24346. [PMID: 35293027 DOI: 10.1002/jcla.24346] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 7 |
Zhao Z, Wang C, Chu P, Lu X. Key Genes Associated with Tumor-Infiltrating Non-regulatory CD4- and CD8-Positive T Cells in Microenvironment of Hepatocellular Carcinoma. Biochem Genet. [DOI: 10.1007/s10528-021-10175-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 8 |
Zou B, Guo D, Kong P, Wang Y, Cheng X, Cui Y. Integrative Genomic Analyses of 1,145 Patient Samples Reveal New Biomarkers in Esophageal Squamous Cell Carcinoma. Front Mol Biosci 2022;8:792779. [DOI: 10.3389/fmolb.2021.792779] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
张 爱. Advances in the Application of Tumor Mutation Burden in Hepatocellular Carcinoma. ACM 2022;12:1724-1729. [DOI: 10.12677/acm.2022.123248] [Reference Citation Analysis]
|
| 10 |
Huang C, Zhang C, Sheng J, Wang D, Zhao Y, Qian L, Xie L, Meng Z. Identification and Validation of a Tumor Microenvironment-Related Gene Signature in Hepatocellular Carcinoma Prognosis. Front Genet 2021;12:717319. [PMID: 34899826 DOI: 10.3389/fgene.2021.717319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 11 |
Franses JW, Bhan I, Pankaj A, Ting DT, Deshpande V, Tanabe K. Spontaneous Immune-Mediated Regression of Hepatocellular Carcinoma With High Tumor Mutational Burden. JCO Precis Oncol 2021;5:PO. [PMID: 34585041 DOI: 10.1200/PO.21.00092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 12 |
Qi F, Du X, Zhao Z, Zhang D, Huang M, Bai Y, Yang B, Qin W, Xia J. Tumor Mutation Burden-Associated LINC00638/miR-4732-3p/ULBP1 Axis Promotes Immune Escape via PD-L1 in Hepatocellular Carcinoma. Front Oncol 2021;11:729340. [PMID: 34568062 DOI: 10.3389/fonc.2021.729340] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 13 |
Shrestha R, Bridle KR, Crawford DHG, Jayachandran A. Immune checkpoint molecules are regulated by transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma. Int J Med Sci 2021;18:2466-79. [PMID: 34104078 DOI: 10.7150/ijms.54239] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
|
